CN108495927A - 嵌合抗原受体相关的方法和组合物 - Google Patents

嵌合抗原受体相关的方法和组合物 Download PDF

Info

Publication number
CN108495927A
CN108495927A CN201680079790.4A CN201680079790A CN108495927A CN 108495927 A CN108495927 A CN 108495927A CN 201680079790 A CN201680079790 A CN 201680079790A CN 108495927 A CN108495927 A CN 108495927A
Authority
CN
China
Prior art keywords
domain
protein interaction
cells
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680079790.4A
Other languages
English (en)
Chinese (zh)
Inventor
威尔逊·翁
赵章桓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of CN108495927A publication Critical patent/CN108495927A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN201680079790.4A 2015-11-23 2016-11-22 嵌合抗原受体相关的方法和组合物 Pending CN108495927A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258712P 2015-11-23 2015-11-23
US62/258,712 2015-11-23
PCT/US2016/063257 WO2017091546A1 (en) 2015-11-23 2016-11-22 Methods and compositions relating to chimeric antigen receptors

Publications (1)

Publication Number Publication Date
CN108495927A true CN108495927A (zh) 2018-09-04

Family

ID=58764335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680079790.4A Pending CN108495927A (zh) 2015-11-23 2016-11-22 嵌合抗原受体相关的方法和组合物

Country Status (7)

Country Link
US (2) US11530252B2 (https=)
EP (1) EP3380602A4 (https=)
JP (1) JP7621053B2 (https=)
KR (2) KR20180075689A (https=)
CN (1) CN108495927A (https=)
HK (1) HK1259190A1 (https=)
WO (1) WO2017091546A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151999A (zh) * 2019-05-22 2019-08-23 中国人民解放军第四军医大学 用于抑制恶性黑色素瘤进展的靶向药物
CN111234033A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
CN111454909A (zh) * 2019-01-22 2020-07-28 北京大学深圳研究生院 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
CN115175935A (zh) * 2019-10-18 2022-10-11 波士顿大学董事会 Cal-t构建体及其用途

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016168773A2 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US11701387B2 (en) 2018-01-04 2023-07-18 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for BDCA2 antigen
WO2019152957A1 (en) * 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
EP3775902B1 (en) * 2018-04-04 2023-02-22 F. Hoffmann-La Roche AG Diagnostic assays to detect tumor antigens in cancer patients
US20210145830A1 (en) * 2018-04-05 2021-05-20 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
WO2020037178A1 (en) * 2018-08-16 2020-02-20 Memorial Sloan-Kettering Cancer Center Leucine zipper-based compositions and methods of use
EP4588483A3 (en) * 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US20220133791A1 (en) 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
EP3946382A1 (en) 2019-04-04 2022-02-09 UMC Utrecht Holding B.V. Modified immune receptor constructs
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
EP3997129B1 (en) 2019-07-11 2025-11-26 Valkyr, Inc. System and methods relating to chimeric autoantibody receptors
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
EP4073103A1 (en) 2019-12-11 2022-10-19 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
EP4100027A1 (en) 2020-02-04 2022-12-14 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN115397845A (zh) * 2020-02-20 2022-11-25 森迪生物科学公司 抑制性嵌合受体架构
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
US20210322471A1 (en) * 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20240252641A1 (en) * 2020-05-05 2024-08-01 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
JP2023525910A (ja) 2020-05-20 2023-06-19 ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー Ｃｄ９０およびｃｄ３２６を発現しているがんを処置するための組成物および方法
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
IL300484A (en) 2020-08-19 2023-04-01 Astellas Pharma Inc A human non-naturally occurring modified IgG FC region that specifically binds to a non-naturally occurring modified FC receptor
AU2021328478A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
KR102859550B1 (ko) 2020-08-20 2025-09-16 에이투 바이오쎄라퓨틱스, 인크. Ceacam 양성 암을 치료하기 위한 조성물 및 방법
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2022049217A1 (en) 2020-09-04 2022-03-10 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
WO2022081841A1 (en) * 2020-10-16 2022-04-21 Fred Hutchinson Cancer Research Center Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
US11819578B2 (en) 2021-10-07 2023-11-21 Trustees Of Boston University Nanofiber scaffolds
WO2023062113A1 (en) 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023187031A1 (en) 2022-04-01 2023-10-05 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
WO2023217796A1 (en) 2022-05-10 2023-11-16 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
US20250339464A1 (en) 2022-05-16 2025-11-06 Miltenyi Biotec B.V. & Co. KG Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
EP4602171A1 (en) 2022-10-15 2025-08-20 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
US12115217B2 (en) 2022-11-18 2024-10-15 Trustees Of Boston University Self-replicating RNA and uses thereof
EP4471067A1 (en) 2023-06-01 2024-12-04 Miltenyi Biotec B.V. & Co. KG A chemically inducible heterodimerizing system and a method for generation thereof
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
EP4545963A1 (en) 2023-10-26 2025-04-30 Miltenyi Biotec B.V. & Co. KG Method for selecting antigen recognizing moieties having specificity for a target structure
WO2025224123A1 (en) 2024-04-25 2025-10-30 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptors specific for fibroblast activation protein
WO2025252326A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
WO2025252325A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012082841A2 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012082841A2 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AARON W REINKE ET AL.: "A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering", 《J AM CHEM SOC》 *
ASHA ACHARYA ET AL: "Experimental identification of homodimerizing B-ZIP families in Homo sapiens", 《J STRUCT BIOL》 *
KATARZYNA URBANSKA ET AL.: "A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor", 《CANCER RES》 *
KOJI TAMADA ET AL.: "Redirecting gene-modified T cells toward various cancer types using tagged antibodies", 《CLIN CANCER RES》 *
ZHUANG LI ET AL.: "A novel variable antibody fragment dimerized by leucine zippers with enhanced neutralizing potency against rabies virus G protein compared to its corresponding single-chain variable antibody fragment", 《MOL IMMUNOL》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454909A (zh) * 2019-01-22 2020-07-28 北京大学深圳研究生院 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
CN111454909B (zh) * 2019-01-22 2024-12-10 北京大学深圳研究生院 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
CN110151999A (zh) * 2019-05-22 2019-08-23 中国人民解放军第四军医大学 用于抑制恶性黑色素瘤进展的靶向药物
CN115175935A (zh) * 2019-10-18 2022-10-11 波士顿大学董事会 Cal-t构建体及其用途
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
CN111234033A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
WO2021147929A1 (zh) * 2020-01-21 2021-07-29 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途

Also Published As

Publication number Publication date
US20230203123A1 (en) 2023-06-29
WO2017091546A1 (en) 2017-06-01
HK1259190A1 (zh) 2019-11-29
US12577288B2 (en) 2026-03-17
US11530252B2 (en) 2022-12-20
KR20180075689A (ko) 2018-07-04
EP3380602A4 (en) 2019-09-25
JP7621053B2 (ja) 2025-01-29
US20180346541A1 (en) 2018-12-06
KR20250134209A (ko) 2025-09-09
EP3380602A1 (en) 2018-10-03
JP2018538277A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
US12577288B2 (en) Methods and compositions relating to chimeric antigen receptors
US10881711B2 (en) Anti-CSPG4 reagents and methods of treating cancer
AU2016206682B2 (en) Treatment of cancer with anti-LAP monoclonal antibodies
US8753640B2 (en) MIC-binding antibodies and methods of use thereof
JP2024069310A (ja) キメラ受容体及びその使用方法
JP2021176863A (ja) 免疫細胞の能力を増強する方法
KR20190057366A (ko) 암의 치료를 위한 키메라 항원 수용체
JP2018531939A (ja) 治療用化合物及び方法
US12559557B2 (en) Methods and compositions relating to anti-PD1 antibody reagents
JP7453971B2 (ja) Ｎｋエンゲージャー分子およびその使用方法
EP3708189A1 (en) Soluble mic neutralizing monoclonal antibody for treating cancer
US20220265847A1 (en) Methods and compositions for treating non-small cell lung cancer
JP2024514149A (ja) ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
TW202134278A (zh) 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
US11623953B2 (en) Antibody constructs and methods of treating cancer
KR20240005850A (ko) Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는키메라 항원 수용체
WO2023155852A1 (zh) 经修饰的免疫效应细胞及其用途
JP7840569B2 (ja) ヒト４－１ｂｂアゴニスト抗体およびその使用方法
TW202547873A (zh) 用於治療微量殘存疾病之ｃｓｆ－１或ｃｓｆ－１ｒ抑制
JP2024517986A (ja) 抗－ＣＤ３００ｃ抗体を利用した併用療法
HK40119929A (zh) 抗ccr8抗体及其用途
HK40026498A (en) Soluble mic neutralizing monoclonal antibody for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259190

Country of ref document: HK